{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:47:55Z","timestamp":1792504075707,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01074-5","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:02:44Z","timestamp":1682658164000},"page":"4011-4019","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study"],"prefix":"10.1007","volume":"23","author":[{"given":"Xiang","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-zhu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"Suppl 1","key":"1074_CR1","doi-asserted-by":"publisher","first-page":"e12514","DOI":"10.1111\/hel.12514","volume":"23","author":"O Sjomina","year":"2018","unstructured":"Sjomina O, Pavlova J, Niv Y, Leja M. Epidemiology of Helicobacter pylori infection. Helicobacter. 2018;23(Suppl 1):e12514. https:\/\/doi.org\/10.1111\/hel.12514.","journal-title":"Helicobacter"},{"issue":"Suppl 1","key":"1074_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hel.12332","volume":"21","author":"M Leja","year":"2016","unstructured":"Leja M, Axon A, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter. 2016;21(Suppl 1):3\u20137. https:\/\/doi.org\/10.1111\/hel.12332.","journal-title":"Helicobacter"},{"issue":"17","key":"1074_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMcp1001110","volume":"362","author":"KE McColl","year":"2010","unstructured":"McColl KE. Clinical practice Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597\u2013604. https:\/\/doi.org\/10.1056\/NEJMcp1001110.","journal-title":"N Engl J Med"},{"issue":"9","key":"1074_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353\u201367. https:\/\/doi.org\/10.1136\/gutjnl-2015-309252.","journal-title":"Gut"},{"issue":"12","key":"1074_CR5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1136\/gutjnl-2017-315363","volume":"67","author":"E Doorakkers","year":"2018","unstructured":"Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67(12):2092\u20136. https:\/\/doi.org\/10.1136\/gutjnl-2017-315363.","journal-title":"Gut"},{"issue":"4","key":"1074_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/gastro\/goz057","volume":"8","author":"N Tsuji","year":"2020","unstructured":"Tsuji N, Umehara Y, Takenaka M, et al. Verrucous antral gastritis in relation to Helicobacter pylori infection, nutrition, and gastric atrophy. Gastroenterol Rep (Oxf). 2020;8(4):293\u20138. https:\/\/doi.org\/10.1093\/gastro\/goz057.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"7","key":"1074_CR7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.cgh.2018.03.013","volume":"16","author":"HB El-Serag","year":"2018","unstructured":"El-Serag HB, Kao JY, Kanwal F, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol. 2018;16(7):992\u20131002. https:\/\/doi.org\/10.1016\/j.cgh.2018.03.013.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1074_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/gut.2006.101634","volume":"56","author":"P Malfertheiner","year":"2007","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56(6):772\u201381. https:\/\/doi.org\/10.1136\/gut.2006.101634.","journal-title":"Gut"},{"issue":"4","key":"1074_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","volume":"12","author":"DY Graham","year":"2007","unstructured":"Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275\u20138. https:\/\/doi.org\/10.1111\/j.1523-5378.2007.00518.x.","journal-title":"Helicobacter"},{"issue":"3","key":"1074_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","volume":"26","author":"L Fischbach","year":"2007","unstructured":"Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343\u201357. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03386.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1074_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41395-018-0132-6","volume":"113","author":"WD Chey","year":"2018","unstructured":"Chey WD, Leontiadis GI, Howden CW, Moss SF. Correction: ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2018;113(7):1102. https:\/\/doi.org\/10.1038\/s41395-018-0132-6.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1074_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51\u201369. https:\/\/doi.org\/10.1053\/j.gastro.2016.04.006.","journal-title":"Gastroenterology"},{"key":"1074_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","journal-title":"Gut"},{"issue":"1","key":"1074_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/MOG.0000000000000497","volume":"35","author":"SM Smith","year":"2019","unstructured":"Smith SM, O\u2019Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol. 2019;35(1):6\u201313. https:\/\/doi.org\/10.1097\/MOG.0000000000000497.","journal-title":"Curr Opin Gastroenterol"},{"issue":"10","key":"1074_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","volume":"2","author":"YT Kuo","year":"2017","unstructured":"Kuo YT, Liou JM, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(10):707\u201315. https:\/\/doi.org\/10.1016\/S2468-1253(17)30219-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1074_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4291\/wjgp.v2.i3.35","volume":"2","author":"VD Francesco","year":"2011","unstructured":"Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: an updated appraisal. World J Gastrointest Pathophysiol. 2011;2(3):35\u201341. https:\/\/doi.org\/10.4291\/wjgp.v2.i3.35.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"3","key":"1074_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.14309\/ajg.0000000000000132","volume":"114","author":"J Yang","year":"2019","unstructured":"Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114(3):437\u201345. https:\/\/doi.org\/10.14309\/ajg.0000000000000132.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1074_CR18","doi-asserted-by":"publisher","first-page":"e12762","DOI":"10.1111\/hel.12762","volume":"25","author":"Z Song","year":"2020","unstructured":"Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial. Helicobacter. 2020;25(6):e12762. https:\/\/doi.org\/10.1111\/hel.12762.","journal-title":"Helicobacter"},{"issue":"4","key":"1074_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","volume":"12","author":"M Sugimoto","year":"2007","unstructured":"Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317\u201323. https:\/\/doi.org\/10.1111\/j.1523-5378.2007.00508.x.","journal-title":"Helicobacter"},{"issue":"6","key":"1074_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330. https:\/\/doi.org\/10.1111\/apt.13325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1074_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019\u201326. https:\/\/doi.org\/10.1136\/gutjnl-2019-319954.","journal-title":"Gut"},{"issue":"3","key":"1074_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"key":"1074_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11070786","author":"J Chen","year":"2022","unstructured":"Chen J, Li P, Huang Y, Guo Y, Ding Z, Lu H. Primary antibiotic resistance of helicobacter pylori in different regions of china: a systematic review and meta-analysis. Pathogens. 2022. https:\/\/doi.org\/10.3390\/pathogens11070786.","journal-title":"Pathogens"},{"issue":"24","key":"1074_CR24","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135(24):2899\u2013910. https:\/\/doi.org\/10.1097\/CM9.0000000000002546.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"1074_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2036.2012.05211.x","volume":"36","author":"AG McNicholl","year":"2012","unstructured":"McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414\u201325. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05211.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1074_CR26","doi-asserted-by":"publisher","first-page":"e12830","DOI":"10.1111\/hel.12830","volume":"26","author":"AW Gunaratne","year":"2021","unstructured":"Gunaratne AW, Hamblin H, Clancy A, et al. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-exploratory study. Helicobacter. 2021;26(5):e12830. https:\/\/doi.org\/10.1111\/hel.12830.","journal-title":"Helicobacter"},{"issue":"12","key":"1074_CR27","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1111\/jgh.15700","volume":"36","author":"C Bunchorntavakul","year":"2021","unstructured":"Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol. 2021;36(12):3308\u201313. https:\/\/doi.org\/10.1111\/jgh.15700.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1074_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1756283X16668093","volume":"9","author":"Y Akazawa","year":"2016","unstructured":"Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016;9(6):845\u201352. https:\/\/doi.org\/10.1177\/1756283X16668093.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"1074_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439\u201343. https:\/\/doi.org\/10.1007\/s40265-015-0368-z.","journal-title":"Drugs"},{"issue":"7","key":"1074_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636\u201348. https:\/\/doi.org\/10.1111\/apt.13121.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1074_CR31","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/ajg.2014.222","volume":"109","author":"CS Park","year":"2014","unstructured":"Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109(10):1595\u2013602. https:\/\/doi.org\/10.1038\/ajg.2014.222.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1074_CR32","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","volume":"155","author":"A Savoldi","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018;155(5):1372\u201382. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.007.","journal-title":"Gastroenterology"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01074-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01074-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01074-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T01:31:46Z","timestamp":1698802306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01074-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01074-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2547217\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}